NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) has announced significant clinical and regulatory advancements for its lead candidates, NEO100 and NEO212, according to an update from Stonegate Capital Partners. The developments mark a meaningful step forward for the company's oncology pipeline, with NEO100 demonstrating promising efficacy in recurrent brain cancer and NEO212 gaining clarity on its regulatory pathway.
The Phase 2a trial of NEO100 met its primary endpoint, showing a six-month progression-free survival (PFS) rate of 48.9% as assessed by RANO 2.0 criteria using Kaplan-Meier estimation, compared to a pre-specified benchmark of 20% (p=0.0047). Additionally, median overall survival (OS) reached 26.09 months, and the treatment was well-tolerated with no major toxicities reported. These results are particularly notable given that current salvage therapy for recurrent brain cancer typically offers only 6–9 months of survival, as cited by management. While the PFS data are encouraging, the survival signal is considered the more critical readout, though confirmation in a randomized trial remains the next hurdle.
The positive readout positions NEO100 for a potential registrational program, with the company intending to request a Type B meeting with the FDA to discuss trial design, endpoints, and approval pathway. This regulatory engagement is seen as the key near-term catalyst for the company. Furthermore, NEO212 has gained regulatory momentum with Phase 2 CMC clearance and FDA feedback indicating a potential accelerated approval pathway.
Beyond the single trial, the investment case for NeOnc is broadening. NEO100 is being explored in additional indications such as meningioma and pediatric brain tumors, while NEO212 offers a differentiated second clinical program. This platform breadth enhances longer-term optionality, although funding remains a critical factor as development activities expand. Financial results for the second quarter of 2026 show R&D expenses increased to $2.6 million from $0.7 million year-over-year, reflecting the accelerated clinical development.
Stonegate Capital Partners, which provided the update, highlighted that the Phase 2a readout materially strengthens the lead program and moves NEO100 toward a registrational-stage opportunity. The favorable tolerability profile supports the potential for chronic, patient-friendly treatment, which could differentiate it in the market. With FDA alignment now the primary focus, NeOnc is poised to define the path forward for NEO100 and potentially NEO212, offering hope for patients with difficult-to-treat brain cancers.
